



DIVISION OF PUBLIC and BEHAVIORAL HEALTH Policy

Control #	Rev.	Type	Title	Effective Date	Page
MME021			Cannabinoid and Terpenoid Testing	2015-08-14	1 of 3

1.0 POLICY

The Nevada Division of Public and Behavioral Health (DPBH or the Division) shall establish a list of cannabinoids and terpenoids for which medical marijuana will be tested. This policy is in accordance with NRS 453A.368 which states:

NRS 453A.368 Testing laboratories. [Effective April 1, 2014.]

1. *The Division shall establish standards for and certify one or more private and independent testing laboratories to test marijuana, edible marijuana products and marijuana-infused products that are to be sold in this State.*
2. *Such an independent testing laboratory must be able to determine accurately, with respect to marijuana, edible marijuana products and marijuana-infused products that are sold or will be sold at medical marijuana dispensaries in this State:*
 - (a). *The concentration therein of THC and cannabidiol.*
 - (b). *The presence and identification of molds and fungus.*
 - (c). *The composition of the tested material*
 - (d). *The presence of chemicals in the tested material, including, without limitation, pesticides, herbicides or growth regulators.*

This policy is also in accordance with NAC 453A.658(2) which states:

NAC 453A.658 Sample testing; disposal of samples; standards; laboratory test results; grounds for disciplinary action. ([NRS 453A.370](#))

2. *An independent testing laboratory that receives a sample pursuant to this section shall test the sample for cannabinoids, terpenoids, microbial contaminants, mycotoxins, heavy metals and pesticide chemical residue, residual solvents levels and for purposes of conducting an active ingredient analysis, as specified in the policy manual for independent testing laboratories created by the Division.*

On May 6, 2015, the Independent Laboratory Advisory Council (ILAC) recommended the Division adopt four (4) cannabinoids and ten (10) terpenoids for purposes of laboratory testing pursuant to NRS 453A.368. The Division has adopted these cannabinoids and terpenoids as recommended by the ILAC.

Independent Testing Laboratories shall test for and quantify the presence of the following cannabinoids and terpenoids:



DIVISION OF PUBLIC and BEHAVIORAL HEALTH Policy

Control #	Rev.	Type	Title	Effective Date	Page
MME021			Cannabinoid and Terpenoid Testing	2015-08-14	2 of 3

Cannabinoids	Terpenoids
THC	Alpha-Bisabolol
THCA	Alpha-Humulene
CBD	Alpha-Pinene
CBN	Alpha-Terpinolene
	Beta-Caryophyllene
	Beta-Myrcene
	Beta-Pinene
	Caryophyllene Oxide
	Limonene
	Linalool

2.0 PURPOSE

The purpose of this policy is to provide a list of cannabinoids and terpenoids to be identified and quantified through testing by Independent Testing Laboratories in order to satisfy labeling requirements and provide results to patients.

3.0 SCOPE

This policy applies to all Nevada Medical Marijuana Establishments (MME).

4.0 PROCEDURE

4.1 Each Independent Testing Laboratory will collect a random sample from a cultivator or production facility for testing, as specified in NAC 453A.658, and will test it for the cannabinoids and terpenoids specified in paragraph 1.0 of this policy.

4.2 After identifying and quantifying cannabinoids and terpenoids, Independent Testing Laboratories shall provide this information to the cultivator or production facility from which the sample was drawn.



DIVISION OF PUBLIC and BEHAVIORAL HEALTH Policy

Control #	Rev.	Type	Title	Effective Date	Page
MME021			Cannabinoid and Terpenoid Testing	2015-08-14	3 of 3

4.3 MMEs shall label products to identify the cannabinoid and terpenoid profile, as applicable, in accordance with NAC 453A.508, NAC 453A.510 and NAC 453A.512.

5.0 RELATED DOCUMENTS

Upton, Roy, Lyle Cracker, Mahmoud ElSohly, Aviva Romm, Ethan Russo, and Michelle Sexton. "Cannabis Inflorescence." *American Herbal Pharmacopoeia (2014)*: Print.